For instance, the clinical testing of Zilovertamab vedotin (NCT06395103) has a strong rationale thanks to its targeting of the receptor tyrosine kinase-like orphan receptor 1 (ROR1), a surface protein that is overexpressed in NB and that plays a crucial role in its oncogenesis, with high levels of its mRNA correlating with poor prognosis, as it activates several signaling pathways that promote survival, invasion and metastasis (87, 88). The gene discussed is ROR1; the disease is neuroblastoma.